Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 1/20 | 0.47 |
| ▸ | TRPV4 | Q9HBA0 | 4/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.43 |
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
| ▸ | SGK1 | O00141 | 4/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19682467 | 0.85 | TRPV4 (0.49) | VCAM1TRPV4SLC22A12FBP1MAOA | |
| SCHEMBL12560129 | 0.83 | VCAM1 (0.46) | VCAM1SLC22A12FBP1SGK1MAOA | |
| SCHEMBL12777966 | 0.79 | TRPV4 (0.42) | TRPV4SLC22A12MAOAMAOBMEN1 | |
| SCHEMBL20872675 | 0.79 | MAOB (0.40) | TRPV4SLC22A12MAOAMAOBALDH1A1 | |
| SCHEMBL744084 | 0.79 | TRPV4 (0.40) | TRPV4SLC22A12SGK1ALDH1A1 | |
| SCHEMBL11092715 | 0.79 | ALDH1A1 (0.60) | VCAM1TRPV4SLC22A12FBP1SGK1 | |
| SCHEMBL14775214 | 0.75 | GLA (0.43) | TRPV4SLC22A12MAOBMEN1ALDH1A1 | |
| SCHEMBL19552247 | 0.74 | VCAM1 (0.57) | VCAM1MEN1ALDH1A1KMT2A | |
| SCHEMBL489976 | 0.74 | ALDH1A1 (0.58) | TRPV4SLC22A12FBP1ALDH1A1 | |
| SCHEMBL29948777 | 0.74 | ALDH1A1 (0.58) | TRPV4SLC22A12FBP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3498693-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-10-30 | — | — | EP | disclosed |
| EP-4147700-A1 | N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES FOR USE IN THE TREATMENT OF SICKLE CELL DISEASE | LQT Therapeutics Inc. (CA) | 2023-03-15 | — | — | EP | disclosed |
| CN-109790122-B | Heterocyclic compounds | 武田药品工业株式会社 | 2022-06-24 | — | — | CN | disclosed |
| US-10696651-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-30 | — | — | US | disclosed |
| EP-3498693-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-06-19 | — | — | EP | disclosed |
| US-20190169166-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-06 | — | — | US | disclosed |
| EP-2758399-B1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2017-11-15 | — | — | EP | disclosed |
| US-9718825-B2 | N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals | SANOFI (FR) | 2017-08-01 | — | — | US | disclosed |
| EP-2970259-B1 | N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2016-12-21 | — | — | EP | disclosed |
| US-20160175304-A1 | N-[4-(1H-PYRAZOLO[3,4-b]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2016-06-23 | — | — | US | disclosed |
| EP-2570415-A1 | N-[4-(1h-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals | SANOFI (FR) | 2013-03-20 | — | — | EP | disclosed |
| EP-1761529-B3 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG (CH) | 2011-06-15 | — | — | EP | disclosed |
| US-20100210610-A1 | Organic compounds | BALA KAMLESH JAGDIS | 2010-08-19 | — | — | US | disclosed |
| US-20100204225-A1 | Organic compounds | BALA KAMLESH JAGDIS | 2010-08-12 | — | — | US | disclosed |
| US-7666878-B2 | (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease | NOVARTIS AG (CH) | 2010-02-23 | — | — | US | disclosed |
| US-20080312230-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| US-20080114022-A1 | (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease | NOVARTIS AG (CH) | 2008-05-15 | — | — | US | disclosed |
| EP-1761529-B1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG (CH) | 2007-11-14 | — | — | EP | disclosed |
| EP-1761529-A2 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | Novartis AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005123731-A2 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG (CH) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210610-A1 | Organic compounds | SLC10A6, SLCO1B3, OPRM1 | VCAM1 4112/4885TRPV4 1786/4885SLC22A12 1323/4885 |
| US-10696651-B2 | Heterocyclic compound | EIF2AK4, GCN1, GTF2I | VCAM1 4066/4885TRPV4 3890/4885SLC22A12 340/4885 |
| US-20080114022-A1 | (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease | CCR1, CCL2, CCL11 | VCAM1 130/4885TRPV4 1567/4885SLC22A12 3038/4885 |
| US-20190169166-A1 | HETEROCYCLIC COMPOUND | EIF2AK4, GCN1, GTF2I | VCAM1 4066/4885TRPV4 3890/4885SLC22A12 340/4885 |
| US-20100204225-A1 | Organic compounds | SLC10A6, SLCO1B3, OPRM1 | VCAM1 4112/4885TRPV4 1786/4885SLC22A12 1323/4885 |
| US-20160175304-A1 | N-[4-(1H-PYRAZOLO[3,4-b]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SGK1, SGK3, SGK2 | VCAM1 3226/4885TRPV4 817/4885SLC22A12 4485/4885 |
| US-20080312230-A1 | Organic Compounds | OPRM1, OPRL1, OPRD1 | VCAM1 3868/4885TRPV4 41/4885SLC22A12 2148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.